

# Pasternak Pharmacoepidemiology Research Team, Karolinska Institutet

**First published:** 21/12/2022

**Last updated:** 22/12/2022

**Institution**

Educational Institution

Hospital/Clinic/Other health care facility

Laboratory/Research/Testing facility

## Institution identification

### Institution ID

50288

---

### Institution countries

 Sweden

---

### Type of institution

Educational Institution

Hospital/Clinic/Other health care facility

Laboratory/Research/Testing facility

---

### Institution website

<https://staff.ki.se/people/bjorn-pasternak>

---

### ENCePP partner

Yes

## Institution description

Pasternak Pharmacoepidemiology Research Team at Karolinska Institutet Thriving on substantial expertise in large-scale register studies of adverse drug effects, the team's overall objective is to use high-quality epidemiology to help inform evidence-based decisions in clinical practice. We have ongoing research programs in pediatric pharmacoepidemiology, safety and effectiveness of new diabetes drugs, cardiovascular drug safety, and the area of expedited assessment of current drug safety concerns. The team's scope is not limited to one single disease entity or therapeutic area, rather, we are in a constant process of seeking out and addressing emerging drug safety concerns and effectiveness questions with implications for clinical practice.

## Institution details

**Experience with collecting data directly from individual patients or respondents:**

No

---

**Interest in carrying out research that is funded by pharmaceutical companies:**

No

## Contact

Björn Pasternak [bjorn.pasternak@ki.se](mailto:bjorn.pasternak@ki.se)



[bjorn.pasternak@ki.se](mailto:bjorn.pasternak@ki.se)